Human anti-ANTXR chimeric antigen receptor and its use
By developing chimeric antigen receptor CAR-T cells that recognize anthrax toxin receptors, the problems of toxic side effects and poor treatment effects of traditional cancer treatment methods have been solved, and efficient treatment of cancers such as pancreatic cancer has been achieved.
Patent Information
- Application Number
- CN201980091396.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Priority Date
- 2018-12-06
- Filing Date
- 2019-12-06
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2039-12-06
AI Technical Summary
Existing cancer treatment methods such as chemotherapy and radiation therapy have serious toxicity-related side effects, and the practicality of the treatment strategies is limited. Traditional therapeutic antibody drugs have poor pharmacokinetic characteristics, rapid removal of antibodies by serum proteases, and glomeruli. Low filtration and target antigen expression levels lead to limited therapeutic effects.
Develop nucleic acids encoding chimeric antigen receptors (CARs), including extracellular binding domains, transmembrane domains and intracellular signaling domains, specifically identify anthrax toxin receptor ANTXR, prepared by introducing recombinant cells for prevention or A pharmaceutical composition for treating solid cancers, using CAR-T cells to target and kill cancer cells.
It has achieved efficient treatment of specific cancers such as pancreatic cancer, reduced side effects, improved anti-cancer cytotoxicity and activity, and showed potential clinical effectiveness.
Smart Images

Figure CN113396159B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to a chimeric antigen receptor comprising a ligand that specifically targets anthrax toxin receptor (ANTXR), and more specifically, to a nucleic acid encoding a chimeric antigen receptor (which comprises a PA63 ligand that specifically binds to anthrax toxin receptor 1 (ANTXR1) or anthrax toxin receptor 2 (ANTXR2)), a vector comprising the nucleic acid encoding the chimeric antigen receptor, a recombinant cell comprising the vector, a pharmaceutical composition for preventing or treating solid cancer comprising the recombinant cell, and a method for treating solid cancer using the composition. Background Art
[0002] Anthrax toxin receptors (ANTXRs) include anthrax toxin receptor 1 (ANTXR1) and anthrax toxin receptor 2 (ANTXR2), and their known ligands include anthrax toxin secreted by anthrax bacteria. Anthrax toxin is secreted by Bacillus anthracis, which is a Gram-positive bacterium and contains three toxin proteins, namely protective antigen (PA, 83 kDa), lethal factor (LF, 90 kDa) and edema factor (EF, 89 kDa) (Morton, N. (2001) New Engl. J. Med. 345: 1621-1626). Among them, PA binds to the anthrax toxin receptor (ANTXR) on the cell surface, wherein the amino terminal 20 kDa (PA20) is cleaved by furin protease to form a heptamer with a 63 kDa protein (PA63), which then binds to LF (Collier, RJ (2003) Annu. Rev. Cell Dev. Biol. 19: 45-70).
[0003] ANTXR1 is an extracellular matrix protein, also known as "TEM8 (tumor endothelial marker 8)". ANTXR1 is a type I transmembrane protein expressed in the endothelium of various tumors. It has been found to be actively expressed during tumor angiogenesis (St. Croix et al., (2000) Sciences 289: 1197), and it is also known to participate in cell adhesion and migration through extracellular matrix proteins in vascular endothelial cells of tumors (Bradely et al., (2001) Nature 414: 228-229; Nanda et al., (2004) Curr. Opin. Oncol. 16: 44-49). Because ANTXR1 acts as a receptor for extracellular ligands, it has always been a target for the treatment of angiogenesis (Carson-Walter, EB et al., (2001) Cancer Res 61: 6649). However, the effect of ANTXR1 on pancreatic cancer tissue has not been reported. ANTXR2 is also known as "CMG2 (capillary morphogenetic gene 2)", and is known to be involved in angiogenesis. In addition, ANTXR2 is known to be involved in the adhesion and movement of several types of cells, including epithelial cells and endothelial cells (Lin Ye et al., (2014) INTERNATIONAL JOURNAL OF ONCOLOGY 45: 1565-1573).
[0004] Although advances have been made in the detection, prevention, and treatment of cancer, successful therapeutic strategies in general have not been achieved. Various forms of adverse events in cancer therapy result from conventional approaches to treating cancer, including chemotherapy and radiation therapy. As a result, these approaches have limited utility due to severe toxicity-related side effects. Immunotherapy using therapeutic antibodies has limited success due to poor pharmacokinetic profiles, rapid removal of the antibody by serum proteases, filtration in the glomeruli, limited penetration into tumor sites, and expression levels of the target antigen on tumor cells.
[0005] In recent years, the use of genetically modified cell therapy as a new quantum immunogene therapy for cancer has received great attention. This therapy involves introducing a nucleic acid molecule encoding a chimeric antigen receptor (CAR) that is specific to cancer cell surface antigens and can activate cells into T cells or NK cells, proliferating the transgenic cells obtained in vitro, and injecting the transgenic cells. Compared with antibody drugs, this therapy is believed to have a more potent anti-cancer effect for a longer period of time and is therefore expected to be effective in clinical practice.
[0006] In this technical background, as a result of extensive efforts to develop novel chimeric antigen receptors for treating solid cancers, the inventors found that ANTXR1 and ANTXR2 are expressed very little in normal tissues, but are specifically expressed only in pancreatic cancer tissues, and found PA63 ligands that specifically target ANTXR1 and ANTXR2. The present invention was completed based on this discovery.
[0007] The information disclosed in the background is only provided for better understanding of the background of the invention and therefore it may not include information that forms the prior art that is already obvious to those skilled in the art. Summary of the invention
[0008] An object of the present invention is to provide a nucleic acid encoding a chimeric antigen receptor (CAR), wherein the chimeric antigen receptor comprises an extracellular binding domain, a transmembrane domain and an intracellular signaling domain, wherein the extracellular binding domain recognizes anthrax toxin receptor (ANTXR).
[0009] Another object of the present invention is to provide a vector comprising a nucleic acid encoding a chimeric antigen receptor, a recombinant cell comprising the vector, a pharmaceutical composition for preventing or treating solid cancer comprising the recombinant cell, and a method for treating solid cancer using the pharmaceutical composition.
[0010] To achieve the above objectives, the present invention provides a nucleic acid encoding a chimeric antigen receptor (CAR), which comprises an extracellular binding domain, a transmembrane domain and an intracellular signaling domain, wherein the extracellular binding domain recognizes anthrax toxin receptor (ANTXR).
[0011] The present invention also provides a vector comprising a nucleic acid encoding a chimeric antigen receptor (CAR).
[0012] The present invention also provides a recombinant cell comprising the vector.
[0013] The present invention also provides a pharmaceutical composition comprising the recombinant cell for preventing or treating solid cancer.
[0014] The present invention also provides a method for preventing or treating solid cancer, which comprises administering the recombinant cell to a subject.
[0015] The present invention also provides use of the recombinant cells for preventing or treating solid cancers.
[0016] The present invention also provides use of the recombinant cell in preparing a therapeutic agent for preventing or treating solid cancer. Sequence Listing <110> MJ Cell Biology Co., Ltd. <120> Human anti-ANTXR chimeric antigen receptor and its use <130> 0165-PA-013CN <160> 27 <170> PatentIn version 3.5 <210> 1 <211> 568 <212> PRT <213> Artificial Sequence <220> <223> PA63 Ligand <400> 1 Ser Thr Ser Ala Gly Pro Thr Val Pro Asp Arg Asp Asn Asp Gly Ile 1 5 10 15 Pro Asp Ser Leu Glu Val Glu Gly Tyr Thr Val Asp Val Lys Asn Lys 20 25 30 Arg Thr Phe Leu Ser Pro Trp Ile Ser Asn Ile His Glu Lys Lys Gly 35 40 45 Leu Thr Lys Tyr Lys Ser Ser Pro Glu Lys Trp Ser Thr Ala Ser Asp 50 55 60 Pro Tyr Ser Asp Phe Glu Lys Val Thr Gly Arg Ile Asp Lys Asn Val 65 70 75 80 Ser Pro Glu Ala Arg His Pro Leu Val Ala Ala Tyr Pro Ile Val His 85 90 95 Val Asp Met Glu Asn Ile Ile Leu Ser Lys Asn Glu Asp Gln Ser Thr 100 105 110 Gln Asn Thr Asp Ser Gln Thr Arg Thr Ile Ser Lys Asn Thr Ser Thr 115 120 125 Ser Arg Thr His Thr Ser Glu Val His Gly Asn Ala Glu Val His Ala 130 135 140 Ser Phe Phe Asp Ile Gly Gly Ser Val Ser Ala Gly Phe Ser Asn Ser 145 150 155 160 Asn Ser Ser Thr Val Ala Ile Asp His Ser Leu Ser Leu Ala Gly Glu 165 170 175 Arg Thr Trp Ala Glu Thr Met Gly Leu Asn Thr Ala Asp Thr Ala Arg 180 185 190 Leu Asn Ala Asn Ile Arg Tyr Val Asn Thr Gly Thr Ala Pro Ile Tyr 195 200 205 Asn Val Leu Pro Thr Thr Ser Leu Val Leu Gly Lys Asn Gln Thr Leu 210 215 220 Ala Thr Ile Lys Ala Lys Glu Asn Gln Leu Ser Gln Ile Leu Ala Pro 225 230 235 240 Asn Asn Tyr Tyr Pro Ser Lys Asn Leu Ala Pro Ile Ala Leu Asn Ala 245 250 255 Gln Asp Asp Phe Ser Ser Thr Pro Ile Thr Met Asn Tyr Asn Gln Phe 260 265 270 Leu Glu Leu Glu Lys Thr Lys Gln Leu Arg Leu Asp Thr Asp Gln Val 275 280 285 Tyr Gly Asn Ile Ala Thr Tyr Asn Phe Glu Asn Gly Arg Val Arg Val 290 295 300 Asp Thr Gly Ser Asn Trp Ser Glu Val Leu Pro Gln Ile Gln Glu Thr 305 310 315 320 Thr Ala Arg Ile Ile Phe Asn Gly Lys Asp Leu Asn Leu Val Glu Arg 325 330 335 Arg Ile Ala Ala Val Asn Pro Ser Asp Pro Leu Glu Thr Thr Lys Pro 340 345 350 Asp Met Thr Leu Lys Glu Ala Leu Lys Ile Ala Phe Gly Phe Asn Glu 355 360 365 Pro Asn Gly Asn Leu Gln Tyr Gln Gly Lys Asp Ile Thr Glu Phe Asp 370 375 380 Phe Asn Phe Asp Gln Gln Thr Ser Gln Asn Ile Lys Asn Gln Leu Ala 385 390 395 400 Glu Leu Asn Ala Thr Asn Ile Tyr Thr Val Leu Asp Lys Ile Lys Leu 405 410 415 Asn Ala Lys Met Asn Ile Leu Ile Arg Asp Lys Arg Phe His Tyr Asp 420 425 430 Arg Asn Asn Ile Ala Val Gly Ala Asp Glu Ser Val Val Lys Glu Ala 435 440 445 His Arg Glu Val Ile Asn Ser Ser Thr Glu Gly Leu Leu Leu Asn Ile 450 455 460 Asp Lys Asp Ile Arg Lys Ile Leu Ser Gly Tyr Ile Val Glu Ile Glu 465 470 475 480 Asp Thr Glu Gly Leu Lys Glu Val Ile Asn Asp Arg Tyr Asp Met Leu 485 490 495 Asn Ile Ser Ser Leu Arg Gln Asp Gly Lys Thr Phe Ile Asp Phe Lys 500 505 510 Lys Tyr Asn Asp Lys Leu Pro Leu Tyr Ile Ser Asn Pro Asn Tyr Lys 515 520 525 Val Asn Val Tyr Ala Val Thr Lys Glu Asn Thr Ile Ile Asn Pro Ser 530 535 540 Glu Asn Gly Asp Thr Ser Thr Asn Gly Ile Lys Lys Ile Leu Ile Phe 545 550 555 560 Ser Lys Lys Gly Tyr Glu Ile Gly 565 <210> 2 <211> 140 <212> PRT <213> Artificial Sequence <220> <223> D4 <400> 2 Phe His Tyr Asp Arg Asn Asn Ile Ala Val Gly Ala Asp Glu Ser Val 1 5 10 15 Val Lys Glu Ala His Arg Glu Val Ile Asn Ser Ser Thr Glu Gly Leu 20 25 30 Leu Leu Asn Ile Asp Lys Asp Ile Arg Lys Ile Leu Ser Gly Tyr Ile 35 40 45 Val Glu Ile Glu Asp Thr Glu Gly Leu Lys Glu Val Ile Asn Asp Arg 50 55 60 Tyr Asp Met Leu Asn Ile Ser Ser Leu Arg Gln Asp Gly Lys Thr Phe 65 70 75 80 Ile Asp Phe Lys Lys Tyr Asn Asp Lys Leu Pro Leu Tyr Ile Ser Asn 85 90 95 Pro Asn Tyr Lys Val Asn Val Tyr Ala Val Thr Lys Glu Asn Thr Ile 100 105 110 Ile Asn Pro Ser Glu Asn Gly Asp Thr Ser Thr Asn Gly Ile Lys Lys 115 120 125 Ile Leu Ile Phe Ser Lys Lys Gly Tyr Glu Ile Gly 130 135 140 <210> 3 <211> 231 <212> PRT <213> Artificial Sequence <220> <223> D1+D4 <400> 3 Ser Thr Ser Ala Gly Pro Thr Val Pro Asp Arg Asp Asn Asp Gly Ile 1 5 10 15 Pro Asp Ser Leu Glu Val Glu Gly Tyr Thr Val Asp Val Lys Asn Lys 20 25 30 Arg Thr Phe Leu Ser Pro Trp Ile Ser Asn Ile His Glu Lys Lys Gly 35 40 45 Leu Thr Lys Tyr Lys Ser Ser Pro Glu Lys Trp Ser Thr Ala Ser Asp 50 55 60 Pro Tyr Ser Asp Phe Glu Lys Val Thr Gly Arg Ile Asp Lys Asn Val 65 70 75 80 Ser Pro Glu Ala Arg His Pro Leu Val Ala Ala Phe His Tyr Asp Arg 85 90 95 Asn Asn Ile Ala Val Gly Ala Asp Glu Ser Val Val Lys Glu Ala His 100 105 110 Arg Glu Val Ile Asn Ser Ser Thr Glu Gly Leu Leu Leu Asn Ile Asp 115 120 125 Lys Asp Ile Arg Lys Ile Leu Ser Gly Tyr Ile Val Glu Ile Glu Asp 130 135 140 Thr Glu Gly Leu Lys Glu Val Ile Asn Asp Arg Tyr Asp Met Leu Asn 145 150 155 160 Ile Ser Ser Leu Arg Gln Asp Gly Lys Thr Phe Ile Asp Phe Lys Lys 165 170 175 Tyr Asn Asp Lys Leu Pro Leu Tyr Ile Ser Asn Pro Asn Tyr Lys Val 180 185 190 Asn Val Tyr Ala Val Thr Lys Glu Asn Thr Ile Ile Asn Pro Ser Glu 195 200 205 Asn Gly Asp Thr Ser Thr Asn Gly Ile Lys Lys Ile Leu Ile Phe Ser 210 215 220 Lys Lys Gly Tyr Glu Ile Gly 225 230 <210> 4 <211> 369 <212> PRT <213> Artificial Sequence <220> <223> D2+D4 <400> 4 Tyr Pro Ile Val His Val Asp Met Glu Asn Ile Ile Leu Ser Lys Asn 1 5 10 15 Glu Asp Gln Ser Thr Gln Asn Thr Asp Ser Gln Thr Arg Thr Ile Ser 20 25 30 Lys Asn Thr Ser Thr Ser Arg Thr His Thr Ser Glu Val His Gly Asn 35 40 45 Ala Glu Val His Ala Ser Phe Phe Asp Ile Gly Gly Ser Val Ser Ala 50 55 60 Gly Phe Ser Asn Ser Asn Ser Ser Thr Val Ala Ile Asp His Ser Leu 65 70 75 80 Ser Leu Ala Gly Glu Arg Thr Trp Ala Glu Thr Met Gly Leu Asn Thr 85 90 95 Ala Asp Thr Ala Arg Leu Asn Ala Asn Ile Arg Tyr Val Asn Thr Gly 100 105 110 Thr Ala Pro Ile Tyr Asn Val Leu Pro Thr Thr Ser Leu Val Leu Gly 115 120 125 Lys Asn Gln Thr Leu Ala Thr Ile Lys Ala Lys Glu Asn Gln Leu Ser 130 135 140 Gln Ile Leu Ala Pro Asn Asn Tyr Tyr Pro Ser Lys Asn Leu Ala Pro 145 150 155 160 Ile Ala Leu Asn Ala Gln Asp Asp Phe Ser Ser Thr Pro Ile Thr Met 165 170 175 Asn Tyr Asn Gln Phe Leu Glu Leu Glu Lys Thr Lys Gln Leu Arg Leu 180 185 190 Asp Thr Asp Gln Val Tyr Gly Asn Ile Ala Thr Tyr Asn Phe Glu Asn 195 200 205 Gly Arg Val Arg Val Asp Thr Gly Ser Asn Trp Ser Glu Val Leu Pro 210 215 220 Gln Ile Gln Glu Thr Phe His Tyr Asp Arg Asn Asn Ile Ala Val Gly 225 230 235 240 Ala Asp Glu Ser Val Val Lys Glu Ala His Arg Glu Val Ile Asn Ser 245 250 255 Ser Thr Glu Gly Leu Leu Leu Asn Ile Asp Lys Asp Ile Arg Lys Ile 260 265 270 Leu Ser Gly Tyr Ile Val Glu Ile Glu Asp Thr Glu Gly Leu Lys Glu 275 280 285 Val Ile Asn Asp Arg Tyr Asp Met Leu Asn Ile Ser Ser Leu Arg Gln 290 295 300 Asp Gly Lys Thr Phe Ile Asp Phe Lys Lys Tyr Asn Asp Lys Leu Pro 305 310 315 320 Leu Tyr Ile Ser Asn Pro Asn Tyr Lys Val Asn Val Tyr Ala Val Thr 325 330 335 Lys Glu Asn Thr Ile Ile Asn Pro Ser Glu Asn Gly Asp Thr Ser Thr 340 345 350 Asn Gly Ile Lys Lys Ile Leu Ile Phe Ser Lys Lys Gly Tyr Glu Ile 355 360 365 Gly <210> 5 <211> 248 <212> PRT <213> Artificial Sequence <220> <223> D3+D4 <400> 5 Thr Ala Arg Ile Ile Phe Asn Gly Lys Asp Leu Asn Leu Val Glu Arg 1 5 10 15 Arg Ile Ala Ala Val Asn Pro Ser Asp Pro Leu Glu Thr Thr Lys Pro 20 25 30 Asp Met Thr Leu Lys Glu Ala Leu Lys Ile Ala Phe Gly Phe Asn Glu 35 40 45 Pro Asn Gly Asn Leu Gln Tyr Gln Gly Lys Asp Ile Thr Glu Phe Asp 50 55 60 Phe Asn Phe Asp Gln Gln Thr Ser Gln Asn Ile Lys Asn Gln Leu Ala 65 70 75 80 Glu Leu Asn Ala Thr Asn Ile Tyr Thr Val Leu Asp Lys Ile Lys Leu 85 90 95 Asn Ala Lys Met Asn Ile Leu Ile Arg Asp Lys Arg Phe His Tyr Asp 100 105 110 Arg Asn Asn Ile Ala Val Gly Ala Asp Glu Ser Val Val Lys Glu Ala 115 120 125 His Arg Glu Val Ile Asn Ser Ser Thr Glu Gly Leu Leu Leu Asn Ile 130 135 140 Asp Lys Asp Ile Arg Lys Ile Leu Ser Gly Tyr Ile Val Glu Ile Glu 145 150 155 160 Asp Thr Glu Gly Leu Lys Glu Val Ile Asn Asp Arg Tyr Asp Met Leu 165 170 175 Asn Ile Ser Ser Leu Arg Gln Asp Gly Lys Thr Phe Ile Asp Phe Lys 180 185 190 Lys Tyr Asn Asp Lys Leu Pro Leu Tyr Ile Ser Asn Pro Asn Tyr Lys 195 200 205 Val Asn Val Tyr Ala Val Thr Lys Glu Asn Thr Ile Ile Asn Pro Ser 210 215 220 Glu Asn Gly Asp Thr Ser Thr Asn Gly Ile Lys Lys Ile Leu Ile Phe 225 230 235 240 Ser Lys Lys Gly Tyr Glu Ile Gly 245 <210> 6 <211> 280 <212> PRT <213> Artificial Sequence <220> <223> D4+D4 <400> 6 Phe His Tyr Asp Arg Asn Asn Ile Ala Val Gly Ala Asp Glu Ser Val 1 5 10 15 Val Lys Glu Ala His Arg Glu Val Ile Asn Ser Ser Thr Glu Gly Leu 20 25 30 Leu Leu Asn Ile Asp Lys Asp Ile Arg Lys Ile Leu Ser Gly Tyr Ile 35 40 45 Val Glu Ile Glu Asp Thr Glu Gly Leu Lys Glu Val Ile Asn Asp Arg 50 55 60 Tyr Asp Met Leu Asn Ile Ser Ser Leu Arg Gln Asp Gly Lys Thr Phe 65 70 75 80 Ile Asp Phe Lys Lys Tyr Asn Asp Lys Leu Pro Leu Tyr Ile Ser Asn 85 90 95 Pro Asn Tyr Lys Val Asn Val Tyr Ala Val Thr Lys Glu Asn Thr Ile 100 105 110 Ile Asn Pro Ser Glu Asn Gly Asp Thr Ser Thr Asn Gly Ile Lys Lys 115 120 125 Ile Leu Ile Phe Ser Lys Lys Gly Tyr Glu Ile Gly Phe His Tyr Asp 130 135 140 Arg Asn Asn Ile Ala Val Gly Ala Asp Glu Ser Val Val Lys Glu Ala 145 150 155 160 His Arg Glu Val Ile Asn Ser Ser Thr Glu Gly Leu Leu Leu Asn Ile 165 170 175 Asp Lys Asp Ile Arg Lys Ile Leu Ser Gly Tyr Ile Val Glu Ile Glu 180 185 190 Asp Thr Glu Gly Leu Lys Glu Val Ile Asn Asp Arg Tyr Asp Met Leu 195 200 205 Asn Ile Ser Ser Leu Arg Gln Asp Gly Lys Thr Phe Ile Asp Phe Lys 210 215 220 Lys Tyr Asn Asp Lys Leu Pro Leu Tyr Ile Ser Asn Pro Asn Tyr Lys 225 230 235 240 Val Asn Val Tyr Ala Val Thr Lys Glu Asn Thr Ile Ile Asn Pro Ser 245 250 255 Glu Asn Gly Asp Thr Ser Thr Asn Gly Ile Lys Lys Ile Leu Ile Phe 260 265 270 Ser Lys Lys Gly Tyr Glu Ile Gly 275 280 <210> 7 <211> 460 <212> PRT <213> Artificial Sequence <220> <223> D1+D2+D4 <400> 7 Ser Thr Ser Ala Gly Pro Thr Val Pro Asp Arg Asp Asn Asp Gly Ile 1 5 10 15 Pro Asp Ser Leu Glu Val Glu Gly Tyr Thr Val Asp Val Lys Asn Lys 20 25 30 Arg Thr Phe Leu Ser Pro Trp Ile Ser Asn Ile His Glu Lys Lys Gly 35 40 45 Leu Thr Lys Tyr Lys Ser Ser Pro Glu Lys Trp Ser Thr Ala Ser Asp 50 55 60 Pro Tyr Ser Asp Phe Glu Lys Val Thr Gly Arg Ile Asp Lys Asn Val 65 70 75 80 Ser Pro Glu Ala Arg His Pro Leu Val Ala Ala Tyr Pro Ile Val His 85 90 95 Val Asp Met Glu Asn Ile Ile Leu Ser Lys Asn Glu Asp Gln Ser Thr 100 105 110 Gln Asn Thr Asp Ser Gln Thr Arg Thr Ile Ser Lys Asn Thr Ser Thr 115 120 125 Ser Arg Thr His Thr Ser Glu Val His Gly Asn Ala Glu Val His Ala 130 135 140 Ser Phe Phe Asp Ile Gly Gly Ser Val Ser Ala Gly Phe Ser Asn Ser 145 150 155 160 Asn Ser Ser Thr Val Ala Ile Asp His Ser Leu Ser Leu Ala Gly Glu 165 170 175 Arg Thr Trp Ala Glu Thr Met Gly Leu Asn Thr Ala Asp Thr Ala Arg 180 185 190 Leu Asn Ala Asn Ile Arg Tyr Val Asn Thr Gly Thr Ala Pro Ile Tyr 195 200 205 Asn Val Leu Pro Thr Thr Ser Leu Val Leu Gly Lys Asn Gln Thr Leu 210 215 220 Ala Thr Ile Lys Ala Lys Glu Asn Gln Leu Ser Gln Ile Leu Ala Pro 225 230 235 240 Asn Asn Tyr Tyr Pro Ser Lys Asn Leu Ala Pro Ile Ala Leu Asn Ala 245 250 255 Gln Asp Asp Phe Ser Ser Thr Pro Ile Thr Met Asn Tyr Asn Gln Phe 260 265 270 Leu Glu Leu Glu Lys Thr Lys Gln Leu Arg Leu Asp Thr Asp Gln Val 275 280 285 Tyr Gly Asn Ile Ala Thr Tyr Asn Phe Glu Asn Gly Arg Val Arg Val 290 295 300 Asp Thr Gly Ser Asn Trp Ser Glu Val Leu Pro Gln Ile Gln Glu Thr 305 310 315 320 Phe His Tyr Asp Arg Asn Asn Ile Ala Val Gly Ala Asp Glu Ser Val 325 330 335 Val Lys Glu Ala His Arg Glu Val Ile Asn Ser Ser Thr Glu Gly Leu 340 345 350 Leu Leu Asn Ile Asp Lys Asp Ile Arg Lys Ile Leu Ser Gly Tyr Ile 355 360 365 Val Glu Ile Glu Asp Thr Glu Gly Leu Lys Glu Val Ile Asn Asp Arg 370 375 380 Tyr Asp Met Leu Asn Ile Ser Ser Leu Arg Gln Asp Gly Lys Thr Phe 385 390 395 400 Ile Asp Phe Lys Lys Tyr Asn Asp Lys Leu Pro Leu Tyr Ile Ser Asn 405 410 415 Pro Asn Tyr Lys Val Asn Val Tyr Ala Val Thr Lys Glu Asn Thr Ile 420 425 430 Ile Asn Pro Ser Glu Asn Gly Asp Thr Ser Thr Asn Gly Ile Lys Lys 435 440 445 Ile Leu Ile Phe Ser Lys Lys Gly Tyr Glu Ile Gly 450 455 460 <210> 8 <211> 477 <212> PRT <213> Artificial Sequence <220> <223> D2+D3+D4 <400> 8 Tyr Pro Ile Val His Val Asp Met Glu Asn Ile Ile Leu Ser Lys Asn 1 5 10 15 Glu Asp Gln Ser Thr Gln Asn Thr Asp Ser Gln Thr Arg Thr Ile Ser 20 25 30 Lys Asn Thr Ser Thr Ser Arg Thr His Thr Ser Glu Val His Gly Asn 35 40 45 Ala Glu Val His Ala Ser Phe Phe Asp Ile Gly Gly Ser Val Ser Ala 50 55 60 Gly Phe Ser Asn Ser Asn Ser Ser Thr Val Ala Ile Asp His Ser Leu 65 70 75 80 Ser Leu Ala Gly Glu Arg Thr Trp Ala Glu Thr Met Gly Leu Asn Thr 85 90 95 Ala Asp Thr Ala Arg Leu Asn Ala Asn Ile Arg Tyr Val Asn Thr Gly 100 105 110 Thr Ala Pro Ile Tyr Asn Val Leu Pro Thr Thr Ser Leu Val Leu Gly 115 120 125 Lys Asn Gln Thr Leu Ala Thr Ile Lys Ala Lys Glu Asn Gln Leu Ser 130 135 140 Gln Ile Leu Ala Pro Asn Asn Tyr Tyr Pro Ser Lys Asn Leu Ala Pro 145 150 155 160 Ile Ala Leu Asn Ala Gln Asp Asp Phe Ser Ser Thr Pro Ile Thr Met 165 170 175 Asn Tyr Asn Gln Phe Leu Glu Leu Glu Lys Thr Lys Gln Leu Arg Leu 180 185 190 Asp Thr Asp Gln Val Tyr Gly Asn Ile Ala Thr Tyr Asn Phe Glu Asn 195 200 205 Gly Arg Val Arg Val Asp Thr Gly Ser Asn Trp Ser Glu Val Leu Pro 210 215 220 Gln Ile Gln Glu Thr Thr Ala Arg Ile Ile Phe Asn Gly Lys Asp Leu 225 230 235 240 Asn Leu Val Glu Arg Arg Ile Ala Ala Val Asn Pro Ser Asp Pro Leu 245 250 255 Glu Thr Thr Lys Pro Asp Met Thr Leu Lys Glu Ala Leu Lys Ile Ala 260 265 270 Phe Gly Phe Asn Glu Pro Asn Gly Asn Leu Gln Tyr Gln Gly Lys Asp 275 280 285 Ile Thr Glu Phe Asp Phe Asn Phe Asp Gln Gln Thr Ser Gln Asn Ile 290 295 300 Lys Asn Gln Leu Ala Glu Leu Asn Ala Thr Asn Ile Tyr Thr Val Leu 305 310 315 320 Asp Lys Ile Lys Leu Asn Ala Lys Met Asn Ile Leu Ile Arg Asp Lys 325 330 335 Arg Phe His Tyr Asp Arg Asn Asn Ile Ala Val Gly Ala Asp Glu Ser 340 345 350 Val Val Lys Glu Ala His Arg Glu Val Ile Asn Ser Ser Thr Glu Gly 355 360 365 Leu Leu Leu Asn Ile Asp Lys Asp Ile Arg Lys Ile Leu Ser Gly Tyr 370 375 380 Ile Val Glu Ile Glu Asp Thr Glu Gly Leu Lys Glu Val Ile Asn Asp 385 390 395 400 Arg Tyr Asp Met Leu Asn Ile Ser Ser Leu Arg Gln Asp Gly Lys Thr 405 410 415 Phe Ile Asp Phe Lys Lys Tyr Asn Asp Lys Leu Pro Leu Tyr Ile Ser 420 425 430 Asn Pro Asn Tyr Lys Val Asn Val Tyr Ala Val Thr Lys Glu Asn Thr 435 440 445 Ile Ile Asn Pro Ser Glu Asn Gly Asp Thr Ser Thr Asn Gly Ile Lys 450 455 460 Lys Ile Leu Ile Phe Ser Lys Lys Gly Tyr Glu Ile Gly 465 470 475 <210> 9 <211> 339 <212> PRT <213> Artificial Sequence <220> <223> D1+D3+D4 <400> 9 Ser Thr Ser Ala Gly Pro Thr Val Pro Asp Arg Asp Asn Asp Gly Ile 1 5 10 15 Pro Asp Ser Leu Glu Val Glu Gly Tyr Thr Val Asp Val Lys Asn Lys 20 25 30 Arg Thr Phe Leu Ser Pro Trp Ile Ser Asn Ile His Glu Lys Lys Gly 35 40 45 Leu Thr Lys Tyr Lys Ser Ser Pro Glu Lys Trp Ser Thr Ala Ser Asp 50 55 60 Pro Tyr Ser Asp Phe Glu Lys Val Thr Gly Arg Ile Asp Lys Asn Val 65 70 75 80 Ser Pro Glu Ala Arg His Pro Leu Val Ala Ala Thr Ala Arg Ile Ile 85 90 95 Phe Asn Gly Lys Asp Leu Asn Leu Val Glu Arg Arg Ile Ala Ala Val 100 105 110 Asn Pro Ser Asp Pro Leu Glu Thr Thr Lys Pro Asp Met Thr Leu Lys 115 120 125 Glu Ala Leu Lys Ile Ala Phe Gly Phe Asn Glu Pro Asn Gly Asn Leu 130 135 140 Gln Tyr Gln Gly Lys Asp Ile Thr Glu Phe Asp Phe Asn Phe Asp Gln 145 150 155 160 Gln Thr Ser Gln Asn Ile Lys Asn Gln Leu Ala Glu Leu Asn Ala Thr 165 170 175 Asn Ile Tyr Thr Val Leu Asp Lys Ile Lys Leu Asn Ala Lys Met Asn 180 185 190 Ile Leu Ile Arg Asp Lys Arg Phe His Tyr Asp Arg Asn Asn Ile Ala 195 200 205 Val Gly Ala Asp Glu Ser Val Val Lys Glu Ala His Arg Glu Val Ile 210 215 220 Asn Ser Ser Thr Glu Gly Leu Leu Leu Asn Ile Asp Lys Asp Ile Arg 225 230 235 240 Lys Ile Leu Ser Gly Tyr Ile Val Glu Ile Glu Asp Thr Glu Gly Leu 245 250 255 Lys Glu Val Ile Asn Asp Arg Tyr Asp Met Leu Asn Ile Ser Ser Leu 260 265 270 Arg Gln Asp Gly Lys Thr Phe Ile Asp Phe Lys Lys Tyr Asn Asp Lys 275 280 285 Leu Pro Leu Tyr Ile Ser Asn Pro Asn Tyr Lys Val Asn Val Tyr Ala 290 295 300 Val Thr Lys Glu Asn Thr Ile Ile Asn Pro Ser Glu Asn Gly Asp Thr 305 310 315 320 Ser Thr Asn Gly Ile Lys Lys Ile Leu Ile Phe Ser Lys Lys Gly Tyr 325 330 335 Glu Ile Gly <210> 10 <211> 25 <212> PRT <213> Artificial Sequence <220> <223> Linker <400> 10 Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly 1 5 10 15 Gly Gly Gly Ser Gly Gly Gly Gly Ser 20 25 <210> 11 <211> 198 <212> DNA <213> Artificial Sequence <220> <223> Transmembrane Domain <400> 11 accacgacgc cagcgccgcg accaccaaca ccggcgccca ccatcgcgtc gcagcccctg 60 tccctgcgcc cagaggcgtg ccggccagcg gcggggggcg cagtgcacac gagggggctg 120 gacttcgcct gtgatatcta catctgggcg cccttggccg ggacttgtgg ggtccttctc 180 ctgtcactgg ttatcacc 198 <210> 12 <211> 341 <212> DNA <213> Artificial Sequence <220> <223> Primary signal transduction domain <400> 12 ctgagagtga agttcagcag gagcgcagac gcccccgcgt accagcaggg ccagaaccag 60 ctctataacg agctcaatct aggacgaaga gaggagtacg atgttttgga caagagacgt 120 ggccgggacc ctgagatggg gggaaagccg agaaggaaga accctcagga aggcctgtac 180 aatgaactgc agaaagataa gatggcggag gcctacagtg agattgggat gaaaggcgag 240 cgccggaggg gcaaggggca cgatggcctt taccagggtc tcagtacagc caccaaggac 300 acctacgacg cccttcacat gcaggccctg ccccctcgct a 341 <210> 13 <211> 204 <212> DNA <213> Artificial Sequence <220> <223> co-stimulatory signaling domain <400> 13 ttttgggtgc tggtggtggt tggtggagtc ctggcttgct atagcttgct agtaacagtg 60 gcctttatta ttttctgggt gaggagtaag aggagcaggc tcctgcacag tgactacatg 120 aacatgactc cccgccgccc cgggcccacc cgcaagcatt accagcccta tgccccacca 180 cgcgacttcg cagcctatcg ctcc 204 <210> 14 <211> 126 <212> DNA <213> Artificial Sequence <220> <223> co-stimulatory signaling domain <400> 14 aaacggggca gaaagaaact cctgtatata ttcaaacaac catttatgag accagtacaa 60 actactcaag aggaagatgg ctgtagctgc cgatttccag aagaagaaga aggaggatgt 120 gaactg 126 <210> 15 <211> 249 <212> DNA <213> Artificial Sequence <220> <223> Transmembrane domain <400> 15 ttcgtgcctg tgttcctgcc tgccaagcct accacaacac ccgctcctag acctccaaca 60 ccagctccaa caatcgccag ccagcctctg tctctgaggc cagaagcttg tagacctgct 120 gctggcggag ccgtgcatac aagaggactg gatttcgcct gcgacatcta catctgggcc 180 cctctggctg gaacatgtgg cgttctgctg ctgagcctgg tcatcaccct gtactgcaac 240 caccggaac 249 <210> 16 <211> 336 <212> DNA <213> Artificial Sequence <220> <223> Primary signal transduction domain <400> 16 agagtgaagt tcagcaggag cgcagacgcc cccgcgtacc agcagggcca gaaccagctc 60 tataacgagc tcaatctagg acgaagagag gagtacgatg ttttggacaa gagacgtggc 120 cgggaccctg agatgggggg aaagccgaga aggaagaacc ctcaggaagg cctgtacaat 180 gaactgcaga aagataagat ggcggaggcc tacagtgaga ttgggatgaa aggcgagcgc 240 cggaggggca aggggcacga tggcctttac cagggtctca gtacagccac caaggacacc 300 tacgacgccc ttcacatgca ggccctgccc cctcgc 336 <210> 17 <211> 123 <212> DNA <213> Artificial Sequence <220> <223> co-stimulatory signaling domain <400> 17 aggagtaaga ggagcaggct cctgcacagt gactacatga acatgactcc ccgccgcccc 60 gggcccaccc gcaagcatta ccagccctat gccccacccac gcgacttcgc agcctatcgc 120 tcc 123 <210> 18 <211> 141 <212> DNA <213> Artificial Sequence <220> <223> co-stimulatory signaling domain <400> 18 cgtttctctg ttgttaaacg gggcagaaag aagctcctgt atatattcaa acaaccattt 60 atgagaccag tacaaactac tcaagaggaa gatggctgta gctgccgatt tccagaagaa 120 gaagaaggag gatgtgaact g 141 <210> 19 <211> 51 <212> DNA <213> Artificial Sequence <220> <223> Signal peptide <400> 19 atgtggctgc agagcctgct gctcttgggc actgtggcct gcagcatctc t 51 <210> 20 <211> 267 <212> DNA <213> Artificial Sequence <220> <223> D1 <400> 20 agtacaagtg ctggacctac ggttccagac cgtgacaatg atggaatccc tgattcatta 60 gaggtagaag gatatacggt tgatgtcaaa aataaaagaa cttttctttc accatggatt 120 tctaatattc atgaaaagaa aggattaacc aaatataaat catctcctga aaaatggagc 180 acggcttctg atccgtacag tgatttcgaa aaggttacag gacggattga taagaatgta 240 tcaccagagg caagacaccc ccttgtg 267 <210> 21 <211> 693 <212> DNA <213> Artificial Sequence <220> <223> D2 <400> 21 gcagcttatc cgattgtaca tgtagatatg gagaatatta ttctctcaaa aaatgaggat 60 caatccacac agaatactga tagtcaaacg agaacaataa gtaaaaatac ttctacaagt 120 aggacacata ctagtgaagt acatggaaat gcagaagtgc atgcgtcgtt ctttgatatt 180 ggtgggagtg tatctgcagg atttagtaat tcgaattcaa gtacggtcgc aattgatcat 240 tcactatc tagcagggga aagaacttgg gctgaaacaa tgggtttaaa taccgctgat 300 acagcaagat taaatgccaa tattagatat gtaaatactg ggacggctcc aatctacaac 360 gtgttaccaa cgacttcgtt agtgttagga aaaaatcaaa cactcgcgac aattaaagct 420 aaggaaaacc aattaagtca aatacttgca cctaataatt attatccttc taaaaacttg 480 gcgccaatcg cattaaatgc acaagacgat ttcagttcta ctccaattac aatgaattac 540 aatcaatttc ttgagttaga aaaaacgaaa caattaagat tagatacgga tcaagtatat 600 gggaatatag caacatacaa ttttgaaaat ggaagagtga gggtggatac aggctcgaac 660 tggagtgaag tgttaccgca aattcaagaa aca 693 <210> 22 <211> 324 <212> DNA <213> Artificial Sequence <220> <223> D3 <400> 22 actgcacgta tcatttttaa tggaaaagat ttaaatctgg tagaaaggcg gatagcggcg 60 gttaatccta gtgatccatt agaaacgact aaaccggata tgacattaaa agaagccctt 120 aaaatagcat ttggatttaa cgaaccgaat ggaaacttac aatatcaagg gaaagacata 180 accgaatttg attttaattt cgatcaacaa acatctcaaa atatcaagaa tcagttagcg 240 gaattaaacg taactaacat atatactgta ttagataaaa tcaaattaaa tgcaaaaatg 300 aatattttaa taagagataa acgt 324 <210> 23 <211> 420 <212> DNA <213> Artificial Sequence <220> <223> D4 <400> 23 tttcattatg atagaaataa catagcagtt ggggctgatg agtcagtagt taaggaggct 60 catagagaag taattaattc gtcaacagag ggattattgt taaatattga taaggatata 120 agaaaaatat tatcaggtta tattgtagaa attgaagata ctgaagggct taaagaagtt 180 ataaatgaca gatatgatat gttgaatatt tctagtttac ggcaagatgg aaaaacattt 240 atagatttta aaaaatataa tgataaatta ccgttatata taagtaatcc caattataag 300 gtaaatgtat atgctgttac taaagaaaac actattatta atcctagtga gaatggggat 360 actagtacca acgggatcaa gaaaatttta atcttttcta aaaaaggcta tgagatagga 420 420 <210> twenty four <211> twenty three <212> DNA <213> Artificial Sequence <220> <223> Primers <400> twenty four tgctgcacca ctggaatgaa atc 23 <210> 25 <211> twenty three <212> DNA <213> Artificial Sequence <220> <223> Primers <400> 25 ctcctcctgg cagaactttc tgg 23 <210> 26 <211> 28 <212> DNA <213> Artificial Sequence <220> <223> Primers <400> 26 ctttcattgt gttttcttct caagcaac 28 <210> 27 <211> 26 <212> DNA <213> Artificial Sequence <220> <223> Primers <400> 27 gttttcaagc ctcctgcttt ctgaat 26 BRIEF DESCRIPTION OF THE DRAWINGS
[0017] Figure 1 The protein expression levels of six major selected genes in normal tissues are shown. A shows the protein expression level of ANTXR1 (anthrax toxin receptor 1), B shows the protein expression level of ANTXR2 (anthrax toxin receptor 2), C shows the protein expression level of TMC5 (transmembrane channel-like 5), D shows the protein expression level of CLDN18 (tight junction protein-18), E shows the protein expression level of MUC13 (mucin 13), and F shows the protein expression level of MMP14 (matrix metalloproteinase 14).
[0018] Figure 2 The expression levels of ANTXR1 and ANTXR2 mRNA in peripheral blood mononuclear cells (PBMC) and primary pancreatic cancer tissues analyzed by real-time RT-PCR (RT-PCR) are shown. PBMC was used as a negative control, PANC-1 was used as a positive control, #101, #103, #105, #106, #107, #108, #109 and #110 were used as stage 2 pancreatic cancer tissues, and #102 was used as stage 3 pancreatic cancer tissues.
[0019] Figure 3 Shown are the expression levels of ANTXR1 and ANTXR2 mRNA in normal cells (HEK-293 cells), MDA-MB 231 cells, and pancreatic cancer cell lines (AsPC1, Capan2, PANC1, Mia-PaCa2, SNU-213, SNU-324, SNU-2466, SNU-2469, SNU-2485, and SNU-2543) analyzed by RT-PCR (real-time RT-PCR).
[0020] Figure 4 Shown are the expression levels of ANTXR1 and ANTXR2 proteins on the cell surface of normal cells (HEK-293 cells), MDA-MB-231 cells, and pancreatic cancer cell lines (AsPC1, PANC1, SNU-213, SNU-2466) analyzed using flow cytometry.
[0021] Figure 5The expression levels of cell surface proteins ANTXR1 and ANTXR2 analyzed by flow cytometry are shown in HUVEC cells (normal cells), MDA-MB 231 cells and pancreatic cancer cell lines (AsPC1, Capan2, PANC1, Mia-PaCa2, SNU-213, SNU-324, SNU-2466, SNU-2469, SNU-2485 and SNU-2543), in which the expression of ANTXR1 and ANTXR2 mRNA was found to be significantly increased after treatment with an agent conjugated with FITC (which shows fluorescence in PA63, a ligand for ANTXR1 and ANTXR2).
[0022] Figure 6 It is a vector map showing the design of CAR specific for ANTXR1 or ANTXR2 of the present invention.
[0023] Figure 6 A shows a CAR comprising a PA63 ligand as an extracellular binding domain, a transmembrane domain derived from CD8α, a G4S1 (GGGGS) linker, a CD3ζ chain as a primary signaling domain, and CD28 and CD137 as co-stimulatory signaling domains. Figure 6 B shows a CAR comprising domain 4 or a fragment comprising domain 4 (as the extracellular binding domain) required for PA63 ligand binding to the receptor, a hinge region and a transmembrane region derived from CD8α, a CD3ζ chain (as the primary signaling domain), and CD28 and CD137 (as co-stimulatory signaling domains).
[0024] Figure 7 Shown is the expression resulting from transduction of CAR into cytotoxic T cell clones analyzed by flow cytometry.
[0025] Figure 8 Conventional NYESO-1 CTLs and CAR-T cells were shown, the former recognizing the NYESO-1 antigen and showing activity, and the latter being able to simultaneously target NYESO-1 and ANTXR1 or ANTXR2 by introducing CAR thereto.
[0026] Fig. 9 The anticancer cell toxicity and activity of D4-containing CAR-T cells against pancreatic cancer cell lines (PANC-1, AsPC1) analyzed by flow cytometry are shown, where "T cells only" represents the negative control and "PMA / ionomycin" represents the positive control.
[0027] Fig.10The anticancer cell toxicity and activity of CAR-T cells containing D4 or D4+D4 against pancreatic cancer cell lines (AsPC1, PANC-1, Mia-PaCa2) were shown.
[0028] Fig.11 The figure shows the anticancer cell toxicity of CAR-T cells containing D4 against a pancreatic cancer cell line (PANC-1).
[0029] Fig.12 The anticancer cell toxicity and activity of CAR-T cells generated using T cells isolated from PBMCs were shown against melanoma (526-mel), pancreatic cancer (PANC-1, Mia-PaCa2), and breast cancer cell lines (SK-BR3, MDA-231, ZR-571).
[0030] Fig.13 The graph shows the cytotoxicity of CAR-T cells generated using T cells isolated from PBMCs against a pancreatic cancer cell line (PANC-1_RFP).
[0031] Fig.14 This is a graph showing the results of applying CAR-T cells generated using T cells isolated from PBMCs to an animal model of pancreatic cancer expressing ANTXR.
[0032] DETAILED DESCRIPTION AND PREFERRED EMBODIMENTS OF THE INVENTION
[0033] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as understood by one of ordinary skill in the art to which the invention belongs. Generally speaking, the terms used herein are well known and commonly used in the art.
[0034] As a result of extensive efforts to develop novel chimeric antigen receptors for the treatment of solid cancers, the inventors have found that ANTXR1 and ANTXR2 are expressed very little in normal tissues and are specifically expressed only in pancreatic cancer tissues. In an embodiment of the present invention, gene changes in cancer tissues, IPMN tissues, and normal pancreatic tissues isolated from pancreatic cancer patients were analyzed using a microarray method, and six genes showing increased expression in pancreatic cancer tissues were selected (Table 1). Among the six initially selected genes, only ANTXR1 and ANTXR2 met all the requirements, namely, the expression level of mRNA should satisfy the relationship of "normal tissue < IPMN tissue < pancreatic ductal adenocarcinoma (PDAC) tissue", the expressed protein should be present on the cell surface, and the gene should be rarely expressed in normal tissues. In addition, according to the present invention, PA63 ligands specifically targeting ANTXR1 and ANTXR2 were identified, and CARs specific for ANTXR1 or ANTXR2 were developed, which were engineered to contain domain 4 or a fragment containing domain 4 (as an extracellular binding domain) necessary for the binding of PA63 ligand to the receptor, a hinge region and transmembrane domain derived from CD8α, a CD3ζ chain (as a primary signaling domain), and CD28 and CD137 (as co-stimulatory signaling domains).
[0035] Thus, in one aspect, the present invention relates to a nucleic acid encoding a chimeric antigen receptor (CAR) comprising an extracellular binding domain, a transmembrane domain, and an intracellular signaling domain, wherein the extracellular binding domain recognizes an anthrax toxin receptor (ANTXR).
[0036] As used herein, the term "chimeric antigen receptor (CAR)" refers to a recombinant polypeptide construct that is engineered to target a target cell and intracellular signaling to an immune effector cell. A CAR is a molecule that is combined with the intracellular domain activated by a T cell receptor to produce a chimeric protein that has antibody-based specificity for a target antigen (e.g., a tumor antigen) and specific anti-tumor cell immune activity against it. As used herein, the term "chimera" refers to an organism composed of different protein parts or DNAs derived from different sources. A CAR comprises at least an extracellular binding domain, a transmembrane domain, and an intracellular signaling domain.
[0037] As used herein, the term "extracellular binding domain" refers to a part of CAR that has the ability to specifically bind to a target antigen. The extracellular binding domain may include any protein, polypeptide, oligopeptide or peptide that maintains the ability to specifically recognize biomolecules (e.g., cell surface receptors, tumor proteins, lipids, polysaccharides, other cell surface target molecules or components thereof) and bind thereto. The binding domain includes any naturally occurring, synthetic, semisynthetic or recombinantly produced counterpart for binding to a target biomolecule.
[0038] As used herein, the term "specific binding" refers to the binding affinity of a molecule to another molecule that is greater than the affinity of background binding. For example, when the extracellular binding domain is about 10 5 M -1 When a target molecule is bound or associated with an affinity of 1 / M or Ka (i.e., having an equilibrium dissociation constant for the specific binding interaction in units of 1 / M) or higher, it specifically binds to it. Alternatively, affinity can be defined as having an equilibrium dissociation constant in units of M (e.g., 10 -5 M to 10 -13 The equilibrium dissociation constant (Kd) of a specific binding interaction (M or less) is quantified.
[0039] The affinity of the extracellular binding domain and CAR according to the present invention can be easily measured by conventional techniques, such as binding, association or displacement analysis using competitive ELISA (enzyme-linked immunosorbent assay) or labeled ligand, or surface plasmon resonance devices such as Biacore T100 (available from Biacore, Inc., Piscataway, New Jersey, USA), or optical biosensors such as the EPIC system and EnSpire (available from Corning and Perkin Elmer, respectively).
[0040] In the present invention, the extracellular binding domain can recognize ANTXR. The extracellular binding domain that recognizes ANTXR can be an antibody, an aptamer, or a ligand that specifically binds to ANTXR, but is not limited thereto.
[0041] In the present invention, the ligand may be a PA63 ligand or a fragment thereof.
[0042] The PA63 ligand can be represented by the amino acid sequence of SEQ ID NO:1.
[0043] In addition, the fragment may be domain 4 of the PA63 ligand or a fragment comprising the domain 4.
[0044] The fragment comprising domain 4 of the PA63 ligand can be represented by the amino acid sequence of SEQ ID NO:2.
[0045] In the present invention, D1 is domain 1 of PA63 ligand, D2 is domain 2 of PA63 ligand, D3 is domain 3 of PA63 ligand, and D4 is domain 4 of PA63 ligand. D1+D4 is defined as a combination of domain 1 and domain 4 of PA63 ligand, D2+D4 is defined as a combination of domain 2 and domain 4 of PA63 ligand, D3+D4 is defined as a combination of domain 3 and domain 4 of PA63 ligand, D4+D4 is defined as a combination of domain 4 and domain 4 of PA63 ligand, D1+D2+D4 is defined as a combination of domain 1, domain 2 and domain 4 of PA63 ligand, and D2+D3+D4 is defined as a combination of domain 1, domain 2 and domain 4 of PA63 ligand. The combination of domain 2, domain 3, and domain 4 of the PA63 ligand, D1+D3+D4 is defined as the combination of domain 1, domain 3, and domain 4 of the PA63 ligand, D4+D4+D1 is defined as the combination of domain 4, domain 4, and domain 1 of the PA63 ligand, D4+D4+D2 is defined as the combination of domain 4, domain 4, and domain 2 of the PA63 ligand, D4+D4+D3 is defined as the combination of domain 4, domain 4, and domain 3 of the PA63 ligand, and D4+D4+D D1+D2 is defined as the combination of domain 4, domain 4, domain 1, and domain 2 of the PA63 ligand, D4+D4+D1+D3 is defined as the combination of domain 4, domain 4, domain 1, and domain 3 of the PA63 ligand, D4+D4+D2+D3 is defined as the combination of domain 4, domain 4, domain 2, and domain 3 of the PA63 ligand, D4+D4+D4 is defined as the combination of domain 4, domain 4, and domain 4 of the PA63 ligand, and D4+D4+D1+D3 is defined as the combination of domain 4, domain 4, domain 1, and domain 3 of the PA63 ligand. 4+D1 is defined as the combination of domain 4, domain 4, domain 4 and domain 1 of PA63 ligand, D4+D4+D4+D2 is defined as the combination of domain 4, domain 4, domain 4 and domain 2 of PA63 ligand, D4+D4+D4+D3 is defined as the combination of domain 4, domain 4, domain 4 and domain 3 of PA63 ligand, and D4+D4+D4+D4 is defined as the combination of domain 4, domain 4, domain 4 and domain 4 of PA63 ligand.
[0046] Fragments comprising domain 4 of the PA63 ligand may be selected from D1+D4, D2+D4, D3+D4, D4+D4, D1+D2+D4, D2+D3+D4, D1+D3+D4, D4+D4+D1, D4+D4+D2, D4+D4+D3, D4+D4+D1+D2, D4+D4+D1+D3, D4+D4+D2+D3, D4+D4+D4, D4+D4+D4+D1, D4+D4+D4+D2, D4+D4+D4+D3 and D4+D4+D4+D4.
[0047] The fragment comprising domain 4 of the PA63 ligand may be selected from the amino acid sequences of SEQ ID NO:2 to SEQ ID NO:9.
[0048] In an embodiment of the present invention, CAR-T cells introduced with D4 or CAR-T cells introduced with D4+D4 have better cytotoxic effects than CAR-T cells containing the PA63 ligand.
[0049] As used herein, the term "PA63" refers to a truncated 63 kDa portion of the protective antigen (PA, 83 kDa), which is the anthrax toxin protein. Anthrax toxin is secreted by Bacillus anthracis, a Gram-positive bacterium.
[0050] In general, it is known that the pathogenicity of anthrax is determined by the ability to produce toxins and capsule formation. Proteins that affect the ability to produce anthrax toxins include protective antigen (PA), edema factor (EF), and lethal factor (LF). None of these exhibit toxicity alone, but protective antigen and edema factor combine to form edema toxin (EdTx), and protective antigen and lethal factor combine to form lethal toxin (LeTx).
[0051] PA binds to a receptor protein (anthrax toxin receptor) on the surface of infectious cell lines such as macrophages, and is then cleaved by furin family proteases into PA20 (20 kDa) and PA63 (63 kDa). It is well known that PA63 becomes a heptamer, binds to LF or EF, and acts as a toxin delivery channel to deliver it into cells.
[0052] This complex enters the cell through the endocytosis mechanism. When the pH value of the endosomal body decreases, the PA63 heptamer changes in structure and a hole is formed on the endosomal membrane. As a result, LF or EF is released into the cytoplasm and becomes toxic (Jiang J. Atomic structure of anthrax protective antigen pore elucidates toxin translocation. Nature. 2015).
[0053] In an embodiment of the present invention, a CAR introducing a nucleic acid encoding D4 and a CAR introducing a nucleic acid encoding D4+D4 were constructed, and it was determined whether the CAR-T cells generated by introducing CAR into T cells showed efficacy in treating pancreatic cancer. The CAR-T cells introduced with nucleic acids encoding D4 or D4+D4 have better efficacy in treating pancreatic cancer than the CAR-T cells introduced with nucleic acids encoding PA63 ligands.
[0054] Therefore, it is obvious to those skilled in the art that all cases in which CAR is constructed by introducing nucleic acids encoding D1+D4, D2+D4, D3+D4, D4+D4, D1+D2+D4, D2+D3+D4, D1+D3+D4, D4+D4+D1, D4+D4+D2, D4+D4+D3, D4+D4+D1+D2, D4+D4+D1+D3, D4+D4+D2+D3, D4+D4+D4, D4+D4+D4+D1, D4+D4+D4+D2, D4+D4+D4+D3 or D4+D4+D4+D4+D4 can exhibit the same or similar effects.
[0055] In the present invention, ANTXR may be ARTXR1 (anthrax toxin receptor 1) or ARTXR2 (anthrax toxin receptor 2).
[0056] As used herein, the term “ANTXR1 (anthrax toxin receptor 1)” refers to an extracellular matrix protein, also known as “TEM8 (tumor endothelial marker 8)”. Its specific nucleic acid sequence can be seen from NCBI (NCBI reference sequence: NM_032208.2).
[0057] As used herein, the term “ANTXR2 (anthrax toxin receptor 2)” means a protein involved in angiogenesis, also known as “CMG2 (capillary morphogenesis gene 2)”. Its specific nucleic acid sequence can be seen from NCBI (NCBI reference sequence: NM_058172.5).
[0058] In addition, in the present invention, the affinity of ANTXR1 and ANTXR2 to PA63 ligand is 170 to 780 μm, which is much higher than the affinity (1 nM Kd) of antibodies for ROR1, EGFR and Her2 / neu, which are previously developed CAR-T cell therapies (Karl A. (2010) Nature precedings 5221:1; Heather MS (2005) Curr. Opin. Microbiol. 8:106-112).
[0059] As used herein, the term "transmembrane domain" refers to a part of CAR that fuses the extracellular binding domain with the intracellular signaling domain and fixes CAR to the plasma membrane of immune effector cells. The transmembrane domain may be derived from natural, synthetic, semisynthetic or recombinant sources. In the present invention, the transmembrane domain is selected from the group consisting of α chain, β chain or ζ chain of a T cell receptor, CD28, CD3ε, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137 and CD154, but is not limited thereto.
[0060] In addition, the transmembrane domain can be attached to the extracellular binding domain by a linker. For example, the linker can be a short oligopeptide linker or a polypeptide linker having a length of 2 to 10 amino acids, and is preferably a glycine (G)-serine (S) doublet, but is not limited thereto. In the present invention, CAR may include G4S1 (GGGGS) (represented by the amino acid sequence of SEQ ID NO: 10) as a linker.
[0061] The binding domain of CAR is usually followed by at least one "hinge domain". As used herein, the term "hinge domain" refers to a part of CAR that is spaced apart from the surface of the effector cell and plays a key role in the positioning of the antigen binding domain to achieve proper cell / cell contact, antigen binding and activation. CAR usually comprises at least one hinge domain between the extracellular binding domain and the transmembrane domain. The hinge domain may be derived from natural, synthetic, semisynthetic or recombinant sources. The hinge domain may include the amino acid sequence of a naturally occurring immunoglobulin hinge region or a modified immunoglobulin hinge region. The term "modified hinge region" refers to (a) a naturally occurring hinge region in which up to 30% of the amino acids are modified (e.g., up to 25%, 20%, 15%, 10% or 5% of the amino acids are substituted or deleted), (b) a portion of a naturally occurring hinge region having a length of at least 10 amino acids (e.g., at least 12, 13, 14 or 15 amino acids), in which up to 30% of the amino acids are modified (e.g., up to 10% or 20% of the amino acids are substituted or deleted). In some embodiments, the present invention relates to a hinge region of a naturally occurring immunoglobulin, wherein at least 25%, 20%, 15%, 10% or 5% of the amino acids are substituted or deleted), or (c) a portion of a naturally occurring hinge region, including a core hinge region (4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15, or at least 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 amino acids in length). In certain embodiments, at least one cysteine residue in a naturally occurring immunoglobulin hinge region can be substituted with at least one other type of amino acid residue (e.g., at least one serine residue). The modified immunoglobulin hinge region can alternatively or additionally have a proline residue of a wild-type immunoglobulin hinge region substituted with another amino acid residue (e.g., a serine residue). The hinge domain may include a hinge region derived from the extracellular region of type 1 membrane proteins such as CD8α, CD4, CD28, and CD7, and may be a wild-type hinge region from these molecules or a modified hinge region therefrom.
[0062] In the present invention, the transmembrane domain bound by the linker may be encoded by the nucleic acid sequence of SEQ ID NO: 11 (derived from CD8α), but is not limited thereto.
[0063] In the present invention, the transmembrane domain including the hinge domain may be encoded by the nucleic acid sequence of SEQ ID NO: 15 (derived from CD8α), but is not limited thereto.
[0064] As used herein, the term "intracellular signaling domain" refers to a portion of a CAR that is involved in effector cell functions, such as activation, including the release of cytotoxic factors, cytokine production, proliferation, and cytotoxic activity to target cells bound to the CAR, or the effective delivery of information about CAR binding to target antigens to immune effector cells to induce other cellular responses caused by the extracellular binding domain of the antigen-binding CAR. Effector function refers to a specific function of a cell. For example, the effector function of a T cell may be a cytolytic activity, an activity including cytokine secretion, or may promote such activity. Therefore, an intracellular signaling domain means a portion of a protein that transmits effector function signals and directs cells to perform specific functions.
[0065] It is known that the signal generated by the T cell receptor alone cannot fully activate T cells, so a costimulatory signal is further required. Therefore, T cell activation is mediated by two different intracellular signaling domains. For example, T cell activation is mediated by a primary signaling domain and a costimulatory signaling domain, wherein the primary signaling domain initiates antigen-dependent primary activation through the T cell receptor, and the costimulatory signaling domain acts in an antigen-independent manner to provide a secondary signal. Therefore, in the present invention, the intracellular signaling domain may include a "primary signaling domain" and a "costimulatory signaling domain".
[0066] As used herein, the term "primary signaling domain" refers to a signaling domain that regulates the initial activation of the T cell receptor complex in a stimulatory or inhibitory manner. A primary signaling domain that acts in a stimulatory manner may contain a signaling motif known as an immunoreceptor tyrosine-based activation motif or ITAM. The ITAM containing the primary signaling domain may be selected from the group consisting of TCRζ, FcRγ, FcRβ, CD3γ, CD3δ, CD3ε, CD3ζ, CD22, CD79a, CD79b, and CD66d, but is not limited thereto.
[0067] In the present invention, the primary signaling domain may be CD3ζ, encoded by the nucleic acid sequence of SEQ ID NO: 12 or SEQ ID NO: 16, but is not limited thereto.
[0068] As used herein, the term "costimulatory signaling domain" refers to the intracellular signaling domain of a costimulatory molecule. Costimulatory molecules are cell surface molecules other than Fc receptors that provide secondary signals required for efficient activation and function of T lymphocytes when binding to antigen receptors or antigens. In the present invention, the costimulatory signaling domain is selected from OX40, CD2, CD27, CD28, CDS, ICAM-1, LFA-1 (CD11a / CD18), ICOS (CD278) and 4-1BB (CD137), but is not limited thereto.
[0069] In the present invention, the costimulatory signaling domain may be CD28 encoded by the nucleic acid sequence of SEQ ID NO: 13 or SEQ ID NO: 17 and CD137 encoded by the nucleic acid sequence of SEQ ID NO: 14 or SEQ ID NO: 18, but is not limited thereto.
[0070] When designing CAR according to the present invention, the nucleic acid encoding the signal peptide can be inserted in front of the PA63 ligand or its fragment. The signal peptide can be GM-CSF, CD8α signal peptide, etc., but GM-CSF is most commonly used in CAR engineering, and GM-CSF is used as a signal peptide in an embodiment of the present invention.
[0071] In another aspect, the invention relates to a vector comprising a nucleic acid encoding a chimeric antigen receptor.
[0072] As used herein, the term "vector" refers to a nucleic acid molecule capable of transferring or transporting another nucleic acid molecule. The transferred nucleic acid is usually connected to a carrier nucleic acid molecule and, for example, is inserted into a carrier nucleic acid molecule. The vector may include a sequence that directs autonomous replication in a cell, or may include a sequence sufficient to achieve integration into a host cell DNA. The vector may be selected from DNA, RNA, a plasmid, a lentiviral vector, an adenoviral vector, and a retroviral vector, but is not limited thereto. The vector is preferably a pMSCV vector, which is a retroviral vector, but is not limited thereto.
[0073] In another aspect, the present invention relates to a recombinant cell comprising the vector.
[0074] As used herein, the term "recombinant cell" refers to a cell that has been genetically modified to express the CAR of the present invention for the treatment of cancer, etc. The term "genetically modified" refers to the addition of exogenous genetic material to the total genetic material of the cell in the form of DNA or RNA.
[0075] In the present invention, cell can be T cell or NK cell.Therefore, the recombinant cell comprising the vector containing the nucleic acid encoding CAR according to the present invention is CAR-T cell (chimeric antigen receptor T cell) or CAR-NK cell (chimeric antigen receptor natural killer cell).
[0076] In the present invention, the T cells are selected from the group consisting of cytotoxic T lymphocytes (CTLs), tumor infiltrating lymphocytes (TILs) and T cells isolated from peripheral blood mononuclear cells (PBMCs).
[0077] Preferably, the cell may be a human CD8+T cell, and the cell used in the embodiment of the present invention may be a NYESO-1T cell, but is not limited thereto.
[0078] In another aspect, the present invention relates to a pharmaceutical composition comprising a recombinant cell for preventing or treating solid cancer.
[0079] In another aspect, the present invention relates to a method for preventing or treating solid cancer, comprising administering the recombinant cell to a subject.
[0080] In another aspect, the present invention relates to the use of recombinant cells for preventing or treating solid cancers.
[0081] In another aspect, the present invention relates to the use of a recombinant cell for preparing a therapeutic agent for preventing or treating solid cancer.
[0082] As used herein, the term "prevention" refers to any effect of inhibiting or delaying the progression of solid cancer by administering the composition of the present invention, and the term "treatment" refers to inhibiting the onset of solid cancer or alleviating or eliminating the symptoms of solid cancer.
[0083] In one embodiment of the present invention, the anticancer cell toxicity of CAR-T cells against pancreatic cancer cells was discovered, but the present invention is not limited thereto.
[0084] It is obvious to those skilled in the art that, based on the cytotoxic action mechanism of PA63, domain 4 of the PA63 ligand according to the present invention or a fragment comprising domain 4 can specifically bind not only to pancreatic cancer cells or tissues, but also to other cancer cells or tissues expressing ANTXR, and CAR-containing cells comprising domain 4 of the PA63 ligand according to the present invention or a fragment comprising domain 4 have a cytotoxic effect on cancers expressing ANTXR.
[0085] In one embodiment of the present invention, it was confirmed that the cytotoxic effect of CAR-T cells comprising a fragment having domain 4 of PA63 ligand is superior to that of CAR-T cells comprising PA63 ligand.
[0086] As used herein, the term "solid cancer" refers to a tumor that is composed of blood vessels or connective tissue and therefore has a predetermined hardness and shape, and is, for example, pancreatic cancer, gastric cancer, colon cancer, lung cancer, breast cancer, germ cell cancer, liver cancer, skin cancer, bladder cancer, prostate cancer, uterine cancer, cervical cancer, ovarian cancer, etc., but is not limited thereto.
[0087] In the present invention, the solid cancer may be pancreatic cancer, gastric cancer, colon cancer, lung cancer, breast cancer, germ cell cancer, liver cancer, skin cancer, bladder cancer, prostate cancer, uterine cancer, cervical cancer or ovarian cancer expressing ANTXR (anthrax toxin receptor), but is not limited thereto, and ANTXR includes ANTXR1 or ANTXR2.
[0088] As used herein, the term "pancreatic cancer" refers to a tumor composed of cancer cells formed in the pancreas. In general, pancreatic ductal carcinoma originating from pancreatic duct cells accounts for about 90% of pancreatic cancer. More than 85% of pancreatic duct cells have point mutations in the K-ras gene, which is activated when pancreatic cancer occurs (Li et al. (2004) Lancet 363:1049-1057; Xiong (2004) Cancer Chem Pharm 54:S69-77). For the early treatment of pancreatic cancer, it is necessary to understand the precancerous lesions of the pancreas and the progression of cancer, and to judge the prognosis according to the stage or size of the cancer. Representative pancreatic precancerous lesions known include pancreatic intraepithelial neoplasia (PanIN), intraductal papillary mucinous neoplasm (IPMN), mucinous cystic neoplasm (MCN), etc. (Hruban RH, (2001) Am. J. Surg. Pathol. 25: 579-586; Ottenhof NA, (2009) Arch. Pathol. Lab. Med. 133: 375-381; Sipos B., (2009) Pancreatology 9: 45-54). In particular, due to the improvement of the resolution of various medical diagnostic imaging systems and the increase in the frequency of health examinations, it has been found that the frequency of IPMN is increasing recently. IPMNs have attracted great interest because they are progenitor lesions for pancreatic cancer, in which benign tumors may gradually develop into malignant tumors, and because pancreatic cancers are frequently associated with such lesions, even in areas distant from the lesion.
[0089] The pharmaceutical composition for preventing or treating solid cancer may further comprise a pharmaceutically acceptable carrier.
[0090] As used herein, the term "pharmaceutically acceptable carrier" refers to a carrier or diluent that does not damage the biological activity or properties of the compound administered and does not stimulate the organism. The pharmaceutically acceptable carrier of the composition formulated into a liquid solution is sterile and biocompatible, and examples thereof include saline, sterile water, buffered saline, albumin injection, glucose solution, maltodextrin solution, glycerol and one or more mixtures thereof. If necessary, other common additives such as antioxidants, buffers and antibacterial agents may be added. In addition, by further adding diluents, dispersants, surfactants, adhesives and lubricants, the composition can be formulated into injectable solutions such as aqueous solutions, suspensions and emulsions, pills, capsules, granules or tablets.
[0091] The pharmaceutical composition according to the present invention can be any one of various oral or parenteral preparations. In this regard, the pharmaceutical composition can be prepared using common diluents or excipients (such as fillers, thickeners, adhesives, wetting agents, disintegrants, surfactants, etc.). Orally administered solid preparations may include tablets, pills, powders, granules, capsules, etc. This solid preparation is prepared by mixing at least one compound with at least one excipient (such as starch, calcium carbonate, sucrose, lactose or gelatin). In addition to simple excipients, lubricants such as magnesium stearate or talcum may also be used. Orally administered liquid preparations may include suspensions, oral liquids, emulsions, syrups, etc. In addition to simple diluents such as water or liquid paraffin, various excipients such as wetting agents, sweeteners, aromatics and preservatives may also be incorporated into liquid preparations. In addition, parenteral preparations include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized agents, suppositories, etc. Useful non-aqueous solvents and suspending solvents include propylene glycol, polyethylene glycol, vegetable oils (such as olive oil) and injectable esters (such as ethyl oleate). The basic ingredients of suppositories include Witepsol, macrogol, Tween 61, cocoa butter, laurel fat, glycerin gelatin and the like.
[0092] Suitable pharmaceutically acceptable carriers and formulations are described in detail in Remington's Pharmaceutical Science (19th edition, 1995).
[0093] The composition of the present invention can be administered orally or parenterally, and parenteral administration can be intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, endothelial administration, topical administration, intranasal administration, intrapulmonary administration, rectal administration, etc. After oral administration, the protein or peptide is digested. Therefore, the oral composition can be coated with an active drug, or can be formulated to prevent the active drug from being degraded in the stomach. In addition, the composition can be administered using any device capable of delivering the active substance to the target cell.
[0094] The appropriate dose of the pharmaceutical composition for preventing or treating solid cancer may vary depending on factors such as the formulation method, administration method, and the patient's age, weight, sex, pathological condition, diet, administration time, administration route, excretion rate, and reactivity. A skilled doctor can easily determine and prescribe a dose effective for the desired treatment or prevention.
[0095] The compositions of the present invention can be administered as a single therapeutic agent or in combination with another therapeutic agent, and can be administered sequentially or simultaneously with a conventional therapeutic agent.
[0096] Hereinafter, the present invention will be described in more detail with reference to the examples. However, it is obvious to those skilled in the art that these examples are provided only for illustrating the present invention and should not be construed as limiting the scope of the present invention.
[0097] Example 1: Identification of Genes Specific to Solid Cancer
[0098] To identify genes specific to solid cancer, tissues related to pancreatic cancer were used as solid cancer. Pancreatic cancer tissues isolated from a total of 104 pancreatic cancer patients (including 3 stage 1 pancreatic cancer patients, 89 stage 3 pancreatic cancer patients, and 12 stage 4 pancreatic cancer patients) were prepared. Then, microarray analysis was used to analyze gene changes in cancer tissues, IPMN tissues, and normal pancreatic tissues, and 6 genes showing increased expression in pancreatic cancer tissues were selected (Table 1).
[0099] [Table 1]
[0100]
[0101]
[0102] Genes that meet all of the following three requirements were further selected from the six preliminarily selected genes.
[0103] 1) Genes whose mRNA expression levels satisfy "normal tissue < IPMN tissue < pancreatic cancer (PDAC) tissue"
[0104] 2) Genes whose expressed proteins are present on the cell surface
[0105] 3) Genes that are hardly expressed in normal tissues
[0106] Figure 1The protein expression levels of 6 initially selected genes in normal tissues are shown, wherein A shows the protein expression level of ANTXR1 (anthrax toxin receptor 1), B shows the protein expression level of ANTXR2 (anthrax toxin receptor 2), C shows the protein expression level of TMC5 (transmembrane channel-like 5), D shows the protein expression level of CLDN18 (tight junction protein-18), E shows the protein expression level of MUC13 (mucin 13), and F shows the protein expression level of MMP14 (matrix metalloproteinase 14).
[0107] All six genes initially selected were expressed on the cell surface and met the above requirements 1) and 2). However, Figure 1 As can be seen in Figure 2, in addition to ANTXR1 and ANTXR2, there are four other genes that are also expressed in normal tissues, so ANTXR1 and ANTXR2 are the only genes that meet all three requirements ( Figure 1 ).
[0108] In order to further detect the actual expression of ANTXR1 and ANTXR2, real-time RT-PCR (RT-PCR) was performed using peripheral blood mononuclear cells (PBMC), primary pancreatic cancer tissues and pancreatic cancer cell lines. PBMC was used as a negative control and PANC-1 was used as a positive control. Specifically, total RNA was extracted using Trizol / chloroform. After mRNA amplification, cDNA was produced using reverse transcriptase. The primers in Table 2 were added and the mRNA expression levels of ANTXR1 and ANTXR2 were detected by real-time RT-PCR. The StepONEplus real-time PCR system (Applied Biosystems) and iTaq Universal SYBR Green Supermix (Bio-rad) were used for analysis. The concentration of cDNA was 0.5 μg / μl, and each primer was used at a concentration of 10 pM. In 40 cycles, denaturation was performed at 95°C for 15 minutes and annealing / extension was performed at 60°C for 60 seconds.
[0109] [Table 2]
[0110]
[0111] The results showed that the expression of ANTXR1 and ANTXR2 mRNA was significantly increased in primary pancreatic cancer tissues ( Figure 2). In addition, the analysis results of HUVEC cells (normal cells), MDA-MB 231 cells and pancreatic cancer cell lines (AsPC1, Capan2, PANC1, Mia-PaCa2, SNU-213, SNU-324, SNU-2466, SNU-2469, SNU-2485, SNU-2543) showed that the expression of ANTXR1 and ANTXR2 mRNA increased in pancreatic cancer cell lines. In particular, in SNU-2466 and SNU-2469, ANTXR1 mRNA expression increased significantly, and in AsPC1, ANTXR2 mRNA expression increased significantly ( Figure 3 ).
[0112] In addition, the expression levels of ANTXR1 and ANTXR2 proteins on the cell surface of normal cells (HUVEC cells), MDA-MB-231 cells and pancreatic cancer cell lines (AsPC1, PANC1, SNU-213, SNU-2466) were analyzed by flow cytometry. The results showed that the expression of ANTXR1 and ANTXR2 proteins increased ( Figure 4 ).
[0113] In addition, after treatment with a FITC-conjugated reagent that shows fluorescence in PA63, which is a ligand for ANTXR1 and ANTXR2, the expression levels of cell surface proteins ANTXR1 and ANTXR2 were again indirectly detected using flow cytometry in normal cells (HUVEC cells), MDA-MB 231 cells, and pancreatic cancer cell lines (AsPC1, Capan2, PANC1, Mia-PaCa2, SNU-213, SNU-324, SNU-2466, SNU-2469, SNU-2485, and SNU-2543) in which ANTXR1 and ANTXR2 mRNA expressions were found to be significantly increased, and the binding of PA63 to ANTXR1 and ANTXR2 was also detected ( Figure 5 ).
[0114] Example 2: Design and construction of ANTXR-specific CAR
[0115] CARs against ANTXR1 or ANTXR2 are designed to include an extracellular binding domain, a transmembrane domain derived from CD8α, a G4S1 (GGGGS) linker or hinge region, the primary signaling domain of the CD3ζ chain, and CD28 and CD137 as co-stimulatory signaling domains.
[0116] A CAR with PA63 ligand as the extracellular binding domain was designed to produce Figure 6 The vector shown in A.
[0117] In addition, CARs introduced with D4, D1+D4, D2+D4, D3+D4, D4+D4, D1+D2+D4, D2+D3+D4, or D1+D3+D4 are designed to include D4 essential for receptor binding of the PA63 ligand as an extracellular binding domain, which is then Figure 6 The vector is introduced at the PA63 site of the vector shown in B to produce a vector. In addition, the CAR is designed to include a nucleic acid encoding a signal peptide in front of D4, D1+D4, D2+D4, D3+D4, D4+D4, D1+D2+D4, D2+D3+D4 or D1+D3+D4.
[0118] The signal peptide has a short amino acid sequence and plays a key role in transporting the synthesized protein to the ER. When the protein reaches the ER, the signal peptide is removed and the protein is transported to the Golgi complex by a carrier. Then, the protein to be expressed on the cell membrane rather than on the intracellular organelles must be transported to the destination. In this example, GM-CSF is used as a signal peptide to transport the synthesized protein to the destination.
[0119] The nucleic acid encoding copGFP was introduced into Figure 6 B vector is used to detect the expression of CAR, but this can be omitted when CAR is actually used as a therapeutic agent.
[0120] Table 3 shows the sequences required to generate CARs comprising PA63 ligands, and Table 4 shows the sequences required to generate CARs comprising fragments of PA63 ligands.
[0121] [Table 3]
[0122]
[0123]
[0124]
[0125] [Table 4]
[0126]
[0127]
[0128]
[0129]
[0130]
[0131]
[0132] The nucleic acids encoding domains 1 to 4 of the PA63 ligand are shown in Table 5 below.
[0133] [Table 5]
[0134]
[0135]
[0136]
[0137] The signal peptide, extracellular binding domain (D4, D1+D4, D2+D4, D3+D4, D4+D4, D1+D2+D4, D2+D3+D4 or D1+D3+D4), transmembrane domain (CD8 transmembrane and hinge) and intracellular signaling domain (CD3, CD134, CD28) of CAR were amplified by PCR and inserted into the TA cloning vector using DNA ligase.
[0138] The TA cloning vector was connected and inserted into a viral vector (pMSCV, pCDH 521a) to express the fusion protein. The virus was produced using a lentiviral vector for introducing CAR and cultured in 293FT cells (5×10 6 ) was induced with an efficiency of about 90% or more in 293FT cells, and the 293FT cells were packaging cells. On the fourth day after the induction of the lentiviral vector, lentivirus was produced, the suspension cell culture medium was recovered and concentrated using an ultracentrifuge at 20,000 rpm for 2 hours, the concentrated lentivirus was transduced into 293FT cells, and the concentration was measured using a flow cytometer. The results showed that at 3.4×10 9 The lentivirus introduced with the CAR gene was obtained with a high yield of IU / ml.
[0139] Example 3: Cultivation of CAR-T cells
[0140] The CAR-containing lentivirus introduced with the PA63 ligand produced in Example 2, D4, D1+D4, D2+D4, D3+D4, D4+D4, D1+D2+D4, D2+D3+D4 or D1+D3+D4 was transduced into the cytotoxic T cell clones isolated from CTL (cytotoxic T lymphocytes) at a concentration of 100 MOI to produce CAR-T cells.
[0141] Using flow cytometry, it was found that the expression was induced with an efficiency of about 47.9%, and the Aria sorter was used to select only the cells in which CAR expression was induced. The rapid expansion protocol (REP) of these cells was initially expanded in vitro to increase the number of CAR cells, and it was observed that pure CAR-T proliferated to a distribution of about 98% on the 10th day of REP ( Figure 7 ).
[0142] The CTL used in this example is NYESO-1CTL (MD Anderson Cancer Center (USA)). Figure 8 Conventional NYESO-1CTL and CAR-T cells are shown. The former recognizes the NYESO-1 antigen and exhibits activity, and the latter can simultaneously target NYESO-1 and ANTXR1 or ANTXR2 by introducing CAR into NYESO-1CTL. The cancer cell types targeted by NYESO-1CTL on the left side of the figure include malignant melanoma and synovial cell sarcoma. NYESO-1CTL can inhibit tumor progression or induce tumor shrinkage.
[0143] In addition, CAR-T cells can be generated by inducing CAR using tumor-infiltrating lymphocytes (TIL) or T cells isolated from peripheral blood mononuclear cells (PBMC).
[0144] Example 4: Confirmation of anticancer cell toxicity of CAR-T cells
[0145] Example 4-1: Confirmation of cytotoxicity against pancreatic cancer cell lines
[0146] In order to confirm the anticancer cell toxicity of the T cells introduced with the D4-containing CAR generated in Example 3 against pancreatic cancer cell lines (PANC-1 and AsPC1), each pancreatic cancer cell line was treated with the T cells introduced with the D4-containing CAR.
[0147] Pancreatic cancer cells were cultured at 1x10 5 Cells / well were seeded into 96-well plates (round bottom) and 1x10 5 Each T cell without CAR, CAR-T containing D4, and CAR-T containing D4+D4 was cultured for 6 hours at 1 cell / well and then treated with Golgi stop to inhibit the release of cytokines. After 6 hours, fixation and permeabilization were performed for intracellular staining, and cells were stained with CD107a and IFNγ antibodies. Then, flow cytometry was used to identify CD107a, which can indirectly detect particle release, and IFNγ, which can detect CAR-T cell activity.
[0148] The results showed that T cells without CAR did not show anticancer cell toxicity or activity against pancreatic cancer cell lines, but CAR-T cells showed anticancer cell toxicity and activity against pancreatic cancer cell lines ( Fig. 9 ).exist Fig. 9 In the experiment, “T cells only” (negative control) were T cells without CAR introduction, and PMA / IONO (positive control) were treated with PMA / ionomycin, which has the function of converting extracellular ions (Ca) into 2+The invention discloses a method for introducing a gene into a cell (e.g., a gene that is expressed in a T cell) and a gene that is expressed in a T cell (e.g., a gene that is expressed in a T cell) and that is used to induce excessive activity of the cell when the T cell is treated with the gene. The gene can be used as an indicator for determining the degree of activity of the T cell.
[0149] Therefore, the effectiveness of CAR-T cells containing PA63 ligand as a therapeutic agent for treating pancreatic cancer can be tested.
[0150] Example 4-2: Anticancer Cell Toxicity to Melanoma Cell Lines and Pancreatic Cancer Cell Lines
[0151] In order to confirm the anticancer cell toxicity of the T cells introduced with the D4-containing CAR and the T cells introduced with the D4+D4-containing CAR generated in Example 3, pancreatic cancer cell lines and melanoma cell lines were treated with these cells, respectively.
[0152] Pancreatic cancer cell lines and melanoma cell lines were each cultured at 1x10 5 Cells / well were seeded into 96-well plates (round bottom) and 1×10 5 Wild-type cells (T cells not introduced with CAR), empty vector controls (T cells expressing vectors not containing D4 or D4+D4), CAR-T containing D4, and CAR-T containing D4+D4 were cultured together for 6 hours, and then treated with Golgi stop to inhibit cytokine release. After 6 hours, fixation and permeabilization were performed for intracellular staining, and the cells were stained with CD107a and IFNγ antibodies. Flow cytometry was then used to identify CD107a, which can indirectly detect particle release, and IFNγ, which can detect CAR-T cell activity. NYESO-1CTL without the introduction of CAR was used as a control.
[0153] NYESO-1 CTL targets melanoma cell lines (526-mel) and thus exhibits anticancer cell toxicity and activity against melanoma cell lines, regardless of the presence or absence of the CAR of the present invention ( Fig.10 ).
[0154] The results of the anticancer cell toxicity test on pancreatic cancer cell lines (AsPC1, PANC-1, Mia-PaCa2) showed that wild-type and empty vector control T cells did not show anticancer cell toxicity or activity against pancreatic cancer cell lines, but T cells introduced with CAR containing D4 and T cells introduced with CAR containing D4+D4 showed anticancer cell toxicity and activity against pancreatic cancer cell lines ( Fig.10 ).
[0155] In addition, the lentivirus introduced with the CAR containing D4, D1+D4, D2+D4, D3+D4 or D1+D2+D3+D4 produced in Example 2 was transduced into the NYESO-1T cell clone at an MOI concentration of 100 to generate CAR-T cells of each lentivirus.
[0156] By centrifugation, 1×10 6 PANC-1 (pancreatic cancer cell line) cells were collected in a 1.5 mL tube, released with 50 μL FBS, and mixed with 50 μL Cr 51 Mix and then stain in a 37°C incubator for 1 hour.
[0157] Then, Cr 51 The stained PANC-1 cells were counted at 1x10 5 Cells / well were seeded in a 96-well plate (round bottom), and then the effector cell (CAR-T): target cell (PANC-1) = 5 (5x10 5 ):1,10(1x10 6 :1, 20(2x10 6 :1 or 40(4x10 6 The cells were cultured with vector control (T cells expressing vector without D4 or each domain), CAR-T containing D4, and CAR-T containing D1+D4, D2+D4, D3+D4, or D1+D2+D3+D4 at a ratio of 1:1 for 4 h, and then the culture medium in each well was collected and Cr was detected using a γ counter. 51 The results showed that, except for CAR-T containing D1+D4, all CAR-Ts showed excellent cytotoxicity, among which CAR-T containing only D4 showed the strongest cytotoxic effect ( Fig.11 ).
[0158] Example 5: Detection of anticancer cell cytotoxicity of CAR-T cells generated by T cells isolated from PBMC against pancreatic cancer and breast cancer
[0159] PBMCs isolated from three healthy donors were transduced with lentiviruses introduced with the D4-containing CAR produced in Example 2 to generate CAR-T cells. In order to detect the anticancer cell toxicity of T cells introduced with the D4-containing CAR, each of the melanoma, pancreatic cancer, and breast cancer cell lines was treated with CAR-T cells.
[0160] Melanoma, pancreatic cancer, and breast cancer cell lines were cultured at 1x10 5 Cells / well were seeded in a 96-well plate (round bottom) and then treated with 1x10 5NT (untransduced) or CAR (CAR-T with D4) of cells / well were cultured for 24 hours. In this case, Golgi termination treatment was performed to inhibit the release of cytokines. After 24 hours, fixation and permeabilization were performed for intracellular staining, and the cells were then stained with IFNγ antibody. IFNγ, which is used to detect CAR-T cell activity, was then analyzed by flow cytometry. Melanoma (526-mel) and breast cancer cell lines (SK-BR3) that do not express ANTXR1 and ANTXR2 were used as controls.
[0161] Melanoma (526-mel) and breast cancer (SK-BR3) cell lines that do not express ANTXR1 and ANTXR2 were not targeted, so no anticancer activity was observed against 526-mel and SK-BR3 cell lines regardless of whether CAR was introduced according to this example ( Fig.12 ).
[0162] At the same time, anticancer cell toxicity was observed against pancreatic cancer cell lines (PANC-1, Mia-PaCa2) and breast cancer cell lines (MDA-231, ZR-571) reported to express ANTXR1 or ANTXR2. The results showed that NT (non-transduced) T cells did not show anticancer cell toxicity and activity, while T cells introduced with D4-containing CAR showed anticancer cell toxicity and activity against pancreatic cancer and breast cancer cell lines ( Fig.12 ). Therefore, CAR-T cells containing PA63 ligands exhibit excellent toxicity against cancer cells expressing ANTXR1 or ANTXR2. Therefore, it is expected that CAR-T cells will exhibit anticancer effects in all forms of cancer expressing ANTXR1 and ANTXR2.
[0163] Example 6: Detection of cytotoxicity of CAR-T cells generated from T cells isolated from PBMC against pancreatic cancer
[0164] A cell line generated by introducing the RFP gene (to show fluorescence in the pancreatic cancer cell line PANC-1) (PANC-1 cell line expressing red fluorescent protein (RFP); PANC-1_RFP) was cultured at 1×10 4 Cells / well were seeded into each well of a 24-well plate, and then the effector cell (CAR-T): target cell (PANC-1) = 5 (5x10 4 ):1,10(1x10 5 :1, 20(2x10 5 :1 or 40(4x10 5): 1 ratio with NT (non-transduced) T cells or CAR (CAR-T containing D4) produced by PBMC from healthy donors were co-cultured for 48 hours. The pancreatic cancer cell line (PANC-1_RFP) retained in a 24-well plate was collected and RFP-positive cells were counted using flow cytometry.
[0165] The results showed that cytotoxicity against pancreatic cancer cell line (PANC-1_RFP) was detected at about 50% (5:1) to about 90% (40:1) ( Fig.13 ).
[0166] Example 7: Animal Model Using CAR-T Cells
[0167] In 1x10 7 Pancreatic cancer cell line (Mia-PaCa2) was subcutaneously injected into immunodeficient mice (Balb / c nude mice, female, 5 weeks old) at a volume of 1x10 cells / 100 μL. 7 PBS, NT (non-transduced), GFP alone (empty vector), and CAR (CAR-T containing D4) were injected intravenously at a concentration of 10 cells / 300 μL. About 4 weeks after cell injection, CAR-T containing D4 showed about 80% tumor volume reduction compared with the control group (PBS, NT, and GFP alone). This shows that CAR-T shows excellent efficacy even in animal models using solid cancers expressing ANTXR1 or ANTXR2 ( Fig.14 ).
[0168] Industrial Applicability
[0169] Solid cancers can be treated using anti-ANTXR chimeric antigen receptor (CAR)-T cells according to the present invention, and efficient and safe customized prevention or treatment of solid cancers is possible while limiting drug administration by administering chimeric antigen receptor (CAR)-T cells to solid cancer patients, particularly pancreatic cancer patients for whom anticancer drugs are ineffective.
[0170] Although the specific configuration of the present invention has been described in detail, it will be appreciated by those skilled in the art that this description is provided to set forth preferred embodiments for illustrative purposes and should not be construed as limiting the scope of the present invention. Therefore, the essential scope of the present invention is defined by the appended claims and their equivalents.
[0171] Unordered text
[0172] Attach electronic file.
Claims
1. A nucleic acid encoding a chimeric antigen receptor (CAR), wherein the chimeric antigen receptor comprises an extracellular binding domain, a transmembrane domain and an intracellular signaling domain, wherein the extracellular binding domain is a fragment comprising domain 4 of the PA63 ligand, the extracellular binding domain is selected from the group consisting of D4, D2+D4, D3+D4, D4+D4 and D1+D2+D3+D4, and recognizes anthrax toxin receptor (ANTXR), Among them, D1 is domain 1 of PA63 ligand, D2 is domain 2 of PA63 ligand, D3 is domain 3 of PA63 ligand, and D4 is domain 4 of PA63 ligand. 2 . The nucleic acid according to claim 1 , wherein the PA63 ligand is represented by the amino acid sequence of SEQ ID NO:
1.
3. The nucleic acid according to claim 1, wherein domain 4 of the PA63 ligand is represented by the amino acid sequence of SEQ ID NO:
2. 4 . The nucleic acid according to claim 1 , wherein the fragment comprising the PA63 ligand domain 4 is selected from the group consisting of the amino acid sequences of SEQ ID NO: 4, SEQ ID NO: 5 and SEQ ID NO:
6.
5. The nucleic acid of claim 1, wherein the ANTXR is ARTXR1 (anthrax toxin receptor 1) or ARTXR2 (anthrax toxin receptor 2).
6. The nucleic acid of claim 1, wherein the transmembrane domain is selected from the group consisting of the α chain, β chain or ζ chain of a T cell receptor, CD28, CD3ε, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD134, CD137 and CD154.
7. The nucleic acid of claim 1, wherein the intracellular signaling domain comprises a primary signaling domain and a co-stimulatory signaling domain.
8. The nucleic acid of claim 7, wherein the primary signaling domain is selected from the group consisting of TCRζ, FcRγ, FcRβ, CD3γ, CD3δ, CD3ε, CD3ζ, CD22, CD79a, CD79b, and CD66d.
9. The nucleic acid of claim 7, wherein the co-stimulatory signaling domain is selected from the group consisting of OX40, CD2, CD27, CD28, CDS, ICAM-1, LFA-1 (CD11a / CD18), ICOS (CD278), and 4-1BB (CD137).
10. A vector comprising a nucleic acid encoding the chimeric antigen receptor according to any one of claims 1 to 9.
11. The vector according to claim 10, wherein the vector is selected from the group consisting of a lentiviral vector, an adenoviral vector and a retroviral vector.
12. A recombinant cell comprising the vector according to claim 11.
13. The recombinant cell of claim 12, wherein the cell is a T cell or a NK cell.
14. The recombinant cell according to claim 13, wherein the T cell is selected from the group consisting of cytotoxic T lymphocytes (CTLs), tumor infiltrating lymphocytes (TILs), and T cells isolated from peripheral blood mononuclear cells (PBMCs).
15. Use of a composition comprising the recombinant cells of claim 12 in the preparation of a therapeutic agent for preventing or treating solid cancers expressing ANTXR (anthrax toxin receptor), wherein the solid cancer expressing ANTXR is selected from the group consisting of pancreatic cancer, gastric cancer, colon cancer, lung cancer, breast cancer, liver cancer, skin cancer, bladder cancer, prostate cancer, uterine cancer, cervical cancer and ovarian cancer.
16. A chimeric antigen receptor comprising an extracellular binding domain, a transmembrane domain and an intracellular signaling domain, wherein the extracellular binding domain is a fragment comprising domain 4 of a PA63 ligand, the extracellular binding domain is selected from the group consisting of D4, D2+D4, D3+D4, D4+D4 and D1+D2+D3+D4, and recognizes anthrax toxin receptor (ANTXR), wherein D1 is domain 1 of a PA63 ligand, D2 is domain 2 of a PA63 ligand, D3 is domain 3 of a PA63 ligand, and D4 is domain 4 of a PA63 ligand.
17. The chimeric antigen receptor according to claim 16, wherein the amino acid sequence of domain 4 of the PA63 ligand is as shown in SEQ ID NO:2.
